{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05848739",
            "orgStudyIdInfo": {
                "id": "ST316-101"
            },
            "organization": {
                "fullName": "Sapience Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors",
            "officialTitle": "A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-phase-of-with-selected-advanced-unresectable-and-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-06-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-05-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-21",
            "studyFirstSubmitQcDate": "2023-04-28",
            "studyFirstPostDateStruct": {
                "date": "2023-05-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sapience Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/\u03b2-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer Metastatic",
                "Pancreatic Cancer",
                "NSCLC, Metastatic",
                "Synovial Sarcoma",
                "Colon Cancer",
                "Metastatic Colon Cancer",
                "Melanoma Recurrent",
                "Metastatic Skin Cancer",
                "Melanoma Stage IV",
                "Triple Negative Breast Cancer",
                "TNBC - Triple-Negative Breast Cancer",
                "Cholangiocarcinoma",
                "Ovarian Cancer",
                "Metastatic Melanoma",
                "Hepatocellular Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 115,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation Phase",
                    "type": "EXPERIMENTAL",
                    "description": "The dose cohorts will be 0.5, 1, 2, 4, 8 \\& 12 mg/kg IV once weekly (QW)",
                    "interventionNames": [
                        "Drug: ST316"
                    ]
                },
                {
                    "label": "ST316 Monotherapy Colon Rectal Cancer (CRC) Expansion phase",
                    "type": "EXPERIMENTAL",
                    "description": "ST316 Monotherapy Colon Rectal Cancer (CRC) Expansion phase n=30",
                    "interventionNames": [
                        "Drug: ST316"
                    ]
                },
                {
                    "label": "ST316 & FOLFIRI/Bevacizumab Combination Colon Rectal Cancer (CRC) Expansion phase",
                    "type": "EXPERIMENTAL",
                    "description": "ST316 \\& FOLFIRI/Bevacizumab Combination Colon Rectal Cancer (CRC) Expansion phase Expansion phase n=30",
                    "interventionNames": [
                        "Drug: ST316",
                        "Drug: FOLFIRI regimen & bevacizumab"
                    ]
                },
                {
                    "label": "ST316 & Fruquintinib Combination CRC Expansion phase",
                    "type": "EXPERIMENTAL",
                    "description": "ST316 \\& Fruquintinib Combination CRC Expansion phase n=30",
                    "interventionNames": [
                        "Drug: ST316",
                        "Drug: Fruquintinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ST316",
                    "description": "IV",
                    "armGroupLabels": [
                        "Dose Escalation Phase",
                        "ST316 & FOLFIRI/Bevacizumab Combination Colon Rectal Cancer (CRC) Expansion phase",
                        "ST316 & Fruquintinib Combination CRC Expansion phase",
                        "ST316 Monotherapy Colon Rectal Cancer (CRC) Expansion phase"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "FOLFIRI regimen & bevacizumab",
                    "description": "FOLFIRI: Days 1 and 15 of each 28-day cycle:\n\n* irinotecan 180 mg/m2 IV over 90 minutes concurrently with\n* leucovorin 400 mg/m2 IV over 2 hours, and then\n* 5-FU bolus 400mg/m2 (up to 15 min infusion)\n* 5-FU 2400 mg/m2 IV over 46 hours\n* bevacizumab should be administered as 5mg/kg.",
                    "armGroupLabels": [
                        "ST316 & FOLFIRI/Bevacizumab Combination Colon Rectal Cancer (CRC) Expansion phase"
                    ],
                    "otherNames": [
                        "FOLFIRI"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fruquintinib",
                    "description": "5 mg once a day for the first 21 days of a 28-day cycle",
                    "armGroupLabels": [
                        "ST316 & Fruquintinib Combination CRC Expansion phase"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with treatment-related adverse events as assessed by CTCAE v5.0",
                    "description": "Number of participants with treatment-related adverse events as assessed by CTCAE v5.0",
                    "timeFrame": "3 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "ST316 PK parameter AUCt",
                    "description": "Area under the concentration-time curve over the dosing interval",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "ST316 Assessment DOR",
                    "description": "DOR is defined for participants achieving a confirmed CR+PR as the time from the initial response of CR+PR per investigator review according to RECIST 1.1 criteria to disease progression or death of any cause, whichever occurs earlier",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "ST316 PK parameter Cmax",
                    "description": "Maximum observed serum concentration",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "ST316 PK parameter t1/2",
                    "description": "half life",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "ST316 PK parameter AUC\u221e",
                    "description": "Area under the concentration-time curve over the dosing interval time from time 0 extrapolated to infinite time",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "ST316 PK parameter tmax.",
                    "description": "The time take to reach Maximum observed serum concentration",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "ST316 Assessment Overall survival (OS)",
                    "description": "Overall survival (OS) is defined as time from first study treatment to death due to any cause.",
                    "timeFrame": "3 Years"
                },
                {
                    "measure": "ST316 Assessment Progression-free survival (PFS)",
                    "description": "Progression-free survival (PFS) is defined as time from first study treatment to a documented disease progression according to RECIST version 1.1, as determined by the investigator, or death due to any cause, whichever occurs earlier.",
                    "timeFrame": "3 Years"
                },
                {
                    "measure": "ST316 Assessment Objective Response Rate (ORR)",
                    "description": "ORR defined as percentage of participants with confirmed best overall response of Confirmed complete response (CR) and partial response (PR) per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.",
                    "timeFrame": "3 Years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Able and willing to sign ICF and comply with the protocol and the restrictions and assessments therein.\n2. Male or female \u226518 years of age.\n3. ECOG performance status 0-1.\n4. Must have a locally advanced or metastatic inoperable tumor as follows:\n\n   1. For the dose escalation/regimen exploration phase: CRC, BC, NSCLC, OC, pancreatic adenocarcinoma, melanoma, CC, and synovial sarcoma.\n   2. For the expansion phase: CRC\n5. Agrees to provide a newly obtained biopsy of an accessible lesion (if they can be biopsied based on the Investigator's assessment) prior to the start of study treatment, and to repeat biopsy once during study treatment. Tissue obtained for the biopsy must not be previously irradiated, but a new or progressing lesion in the radiation field is acceptable. Subjects without accessible lesion for biopsy must be able to provide an archival tumor tissue sample for central lab analysis.\n\n   a. For the dose escalation/regimen exploration phase: i. Refractory, intolerant, or refused all available standard-of-care therapies ii. Up to 3 previous lines of systemic anticancer therapies for metastatic disease are allowed.\n\niii. Patients with TNBC or OC with known BRCA mutations must have been previously treated with or intolerant to FDA approved treatments prior to enrolling in this study (e.g. iPARP).\n\niv. Patients with OC must have been treated with, refused, or were ineligible for treatment with bevacizumab to enroll.\n\nv. Patients with CRC tumors that are MSI-H/dMMR must have received, refused or be intolerant to a check point inhibitor.\n\nb. For the expansion phase: i. For all cohorts: Subjects with MSI-H/dMMR must have received, refused or be intolerant to a CPI.\n\nii. Cohort 1 monotherapy: CRC that has progressed after or on treatment with all of the following, alone or in combination, comprising a maximum of 4 prior lines of therapy for their advanced/metastatic disease: oxaliplatin, irinotecan, fluoropyrimidines, anti-vascular-endothelial growth factor (VEGF), anti-epidermal growth factor receptor (EGFR) targeted agents (as indicated).\n\niii. Cohort 2: Combination with standard of care (SOC) FOLFIRI + bevacizumab: CRC that has progressed after or on treatment with all of the following, alone or in combination, comprising a maximum of 1 prior line of therapy for their advanced/metastatic disease: oxaliplatin, irinotecan, fluoropyrimidines, anti-VEGF. Subjects with RAS wild-type must have been treated with an anti-EGFR targeted agent during the first line of treatment.\n\niv. Cohort 3: Combination with fruquintinib: CRC that has progressed after or on treatment with all of the following, alone or in combination, comprising a maximum of 3 prior lines of therapy for their advanced/metastatic disease: oxaliplatin, irinotecan, fluoropyrimidines, anti-VEGF, regorafenib or lonsurf. Subjects with RAS wild-type must have been treated with an anti-EGFR targeted agent during the first line of treatment.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to ST316 or any of its excipients.\n2. Corrected interval between Q and T wave on ECG (QTc) \\> 480 msec using Fredericia's formula.\n3. Symptomatic ascites or pleural effusion. A subject who is clinically stable for 4 weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.\n4. Known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are clinically stable for at least 2 weeks prior to study entry and have no evidence of new or enlarging brain metastases. Subjects with treated brain metastases must also follow the steroid exclusion criterion (#9) listed below.\n5. For expansion phase only: presence of any other active malignancy requiring systemic therapy other than the disease under study.\n6. Concurrent anti-cancer therapy.\n7. Known HIV and positive -",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Steve Kaesshaefer",
                    "role": "CONTACT",
                    "phone": "9737152917",
                    "email": "steve.kaesshaefer@bexonclinical.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Abi Vainstein-Haras",
                    "affiliation": "CMO",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "USC Norris Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90033",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stephanie Kim",
                            "role": "CONTACT",
                            "email": "Stephanie.Kim2@med.usc.edu"
                        },
                        {
                            "name": "Anthoney El-Khoueiry, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute - CO",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tamara Davidson, MD",
                            "role": "CONTACT",
                            "email": "Tamara.Davidson@sarahcannon.com"
                        },
                        {
                            "name": "Jason Henry, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "START Midwest",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49503",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Julie Burns, BSN",
                            "role": "CONTACT",
                            "email": "Julie.Burns@startmidwest.com"
                        },
                        {
                            "name": "Nehal Lakhani, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "Duke Universtiy",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27708",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "JoAnna Gontarz, MSN",
                            "role": "CONTACT",
                            "email": "joanna.gontarz@duke.edu"
                        },
                        {
                            "name": "Niharika Mettu, MD PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "Sanford Cancer Center",
                    "status": "RECRUITING",
                    "city": "Sioux Falls",
                    "state": "South Dakota",
                    "zip": "57104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Staci Vogel",
                            "role": "CONTACT",
                            "phone": "605-312-3320",
                            "email": "staci.vogel@sanfordhealth.org"
                        },
                        {
                            "name": "Steven Powell, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.54997,
                        "lon": -96.70033
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000008545",
                    "term": "Melanoma"
                },
                {
                    "id": "D000003110",
                    "term": "Colonic Neoplasms"
                },
                {
                    "id": "D000064726",
                    "term": "Triple Negative Breast Neoplasms"
                },
                {
                    "id": "D000018281",
                    "term": "Cholangiocarcinoma"
                },
                {
                    "id": "D000013584",
                    "term": "Sarcoma, Synovial"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000018326",
                    "term": "Nevi and Melanomas"
                },
                {
                    "id": "D000012878",
                    "term": "Skin Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000012509",
                    "term": "Sarcoma"
                },
                {
                    "id": "D000018204",
                    "term": "Neoplasms, Connective and Soft Tissue"
                },
                {
                    "id": "D000015179",
                    "term": "Colorectal Neoplasms"
                },
                {
                    "id": "D000007414",
                    "term": "Intestinal Neoplasms"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000009372",
                    "term": "Neoplasms, Connective Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M9613",
                    "name": "Carcinoma, Hepatocellular",
                    "relevance": "LOW"
                },
                {
                    "id": "M15327",
                    "name": "Sarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M16361",
                    "name": "Sarcoma, Synovial",
                    "asFound": "Synovial Sarcoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15681",
                    "name": "Skin Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "asFound": "Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30373",
                    "name": "Triple Negative Breast Neoplasms",
                    "asFound": "Triple Negative Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M20426",
                    "name": "Cholangiocarcinoma",
                    "asFound": "Cholangiocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6338",
                    "name": "Colonic Neoplasms",
                    "asFound": "Colon Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12448",
                    "name": "Nevus, Pigmented",
                    "relevance": "LOW"
                },
                {
                    "id": "M12446",
                    "name": "Nevus",
                    "relevance": "LOW"
                },
                {
                    "id": "M20470",
                    "name": "Nevi and Melanomas",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M20350",
                    "name": "Neoplasms, Connective and Soft Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M10448",
                    "name": "Intestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12317",
                    "name": "Neoplasms, Connective Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5284",
                    "name": "Soft Tissue Sarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T5553",
                    "name": "Synovial Sarcoma",
                    "asFound": "Synovial Sarcoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T755",
                    "name": "Bile Duct Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068258",
                    "term": "Bevacizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000020533",
                    "term": "Angiogenesis Inhibitors"
                },
                {
                    "id": "D000043924",
                    "term": "Angiogenesis Modulating Agents"
                },
                {
                    "id": "D000006133",
                    "term": "Growth Substances"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000006131",
                    "term": "Growth Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1671",
                    "name": "Irinotecan",
                    "relevance": "LOW"
                },
                {
                    "id": "M8600",
                    "name": "Fluorouracil",
                    "relevance": "LOW"
                },
                {
                    "id": "M246",
                    "name": "Bevacizumab",
                    "asFound": "Non-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6191",
                    "name": "Leucovorin",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M22318",
                    "name": "Angiogenesis Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9231",
                    "name": "Growth Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T120",
                    "name": "Cola",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "HB",
                    "name": "Herbal and Botanical"
                }
            ]
        }
    },
    "hasResults": false
}